Compare Analog Devices, Inc. (ADI) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Analog Devices, Inc. vs Vertex Pharmaceuticals Incorporated — how do they compare? Analog Devices, Inc. trades at $387.69 (market cap $184.62B), while Vertex Pharmaceuticals Incorporated trades at $498.85 (market cap $132.55B). The key difference: Analog Devices, Inc. is the larger of the two by market cap, and Analog Devices, Inc. pays a 1.16% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| ADI | VRTX | |
|---|---|---|
Market Cap | $184.62B | $132.55B |
Sector | Technology | Health |
52-Week High | $445.48 | $529.59 |
52-Week Low | $220.68 | $366.54 |
Enterprise Value | $189.87B | $127.29B |
Dividend Yield | 1.16% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Analog Devices, Inc.
Analog Devices is a leading analog, mixed signal, and digital signal processing chipmaker. The firm has a significant market share lead in converter chips, which are used to translate analog signals to digital and vice versa. The company serves tens of thousands of customers, and more than half of its chip sales are made to industrial and automotive end markets. Analog Devices' chips are also incorporated into wireless infrastructure equipment.
Read more on ADI →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
